Thermo Fisher Scientific Inc. (NYSE:TMO) is Mirova US LLC’s 5th Largest Position

Mirova US LLC decreased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 778,434 shares of the medical research company’s stock after selling 5,018 shares during the period. Thermo Fisher Scientific makes up 6.2% of Mirova US LLC’s portfolio, making the stock its 5th biggest position. Mirova US LLC owned 0.20% of Thermo Fisher Scientific worth $413,185,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently modified their holdings of the stock. Bornite Capital Management LP boosted its holdings in Thermo Fisher Scientific by 50.0% in the first quarter. Bornite Capital Management LP now owns 30,000 shares of the medical research company’s stock valued at $17,719,000 after purchasing an additional 10,000 shares during the last quarter. Fairfield Bush & CO. boosted its holdings in Thermo Fisher Scientific by 1.2% in the first quarter. Fairfield Bush & CO. now owns 2,928 shares of the medical research company’s stock valued at $1,729,000 after purchasing an additional 36 shares during the last quarter. Loomis Sayles & Co. L P boosted its holdings in Thermo Fisher Scientific by 563.5% in the first quarter. Loomis Sayles & Co. L P now owns 19,844 shares of the medical research company’s stock valued at $11,721,000 after purchasing an additional 16,853 shares during the last quarter. Covestor Ltd boosted its holdings in Thermo Fisher Scientific by 60.5% in the first quarter. Covestor Ltd now owns 321 shares of the medical research company’s stock valued at $190,000 after purchasing an additional 121 shares during the last quarter. Finally, Merit Financial Group LLC boosted its holdings in Thermo Fisher Scientific by 3.6% in the first quarter. Merit Financial Group LLC now owns 669 shares of the medical research company’s stock valued at $395,000 after purchasing an additional 23 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently commented on TMO. Barclays downgraded Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and increased their price target for the company from $475.00 to $555.00 in a report on Wednesday, January 24th. TheStreet raised Thermo Fisher Scientific from a “c+” rating to a “b-” rating in a report on Friday, December 22nd. Raymond James increased their target price on Thermo Fisher Scientific from $515.00 to $605.00 and gave the stock an “outperform” rating in a report on Thursday, February 1st. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Thermo Fisher Scientific in a report on Monday, January 8th. Finally, Evercore ISI increased their target price on Thermo Fisher Scientific from $575.00 to $610.00 and gave the stock an “outperform” rating in a report on Thursday, April 4th. Five equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $601.56.

Thermo Fisher Scientific Price Performance

Shares of TMO stock traded down $3.32 during mid-day trading on Wednesday, hitting $554.55. 1,010,299 shares of the stock traded hands, compared to its average volume of 1,115,688. Thermo Fisher Scientific Inc. has a twelve month low of $415.60 and a twelve month high of $603.82. The firm has a market cap of $211.68 billion, a price-to-earnings ratio of 35.90, a price-to-earnings-growth ratio of 2.34 and a beta of 0.80. The company’s 50-day simple moving average is $571.67 and its 200-day simple moving average is $526.87. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.39 and a current ratio of 1.75.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, January 31st. The medical research company reported $5.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.64 by $0.03. Thermo Fisher Scientific had a return on equity of 18.78% and a net margin of 13.99%. The company had revenue of $10.89 billion for the quarter, compared to analysts’ expectations of $10.73 billion. During the same period last year, the firm earned $5.40 EPS. The firm’s revenue for the quarter was down 4.9% on a year-over-year basis. As a group, equities research analysts expect that Thermo Fisher Scientific Inc. will post 21.52 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, April 15th. Stockholders of record on Friday, March 15th were given a dividend of $0.39 per share. The ex-dividend date was Thursday, March 14th. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. This represents a $1.56 annualized dividend and a dividend yield of 0.28%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.10%.

Insider Activity

In other news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $555.63, for a total transaction of $5,556,300.00. Following the completion of the sale, the chief executive officer now directly owns 49,155 shares of the company’s stock, valued at approximately $27,311,992.65. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction on Wednesday, February 7th. The stock was sold at an average price of $555.63, for a total transaction of $5,556,300.00. Following the completion of the sale, the chief executive officer now directly owns 49,155 shares of the company’s stock, valued at approximately $27,311,992.65. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Debora L. Spar sold 164 shares of the firm’s stock in a transaction on Monday, February 12th. The stock was sold at an average price of $546.97, for a total value of $89,703.08. Following the sale, the director now directly owns 1,207 shares of the company’s stock, valued at $660,192.79. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 50,277 shares of company stock worth $28,513,384. 0.32% of the stock is owned by company insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.